As with any medicine, the MHRA will keep the safety and effectiveness of mirdametinib under close review.
Similar Posts
Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets, Chanelle Medical Unlimited Company, EL(25)A/41
Chanelle Medical Unlimited Company has informed the MHRA of an error with the European Article Number (EAN) / Global Trade Item Number (GTIN) barcode on certain batches of Fexofenadine Hydrochloride 120mg film-coated tablets, distributed by Healthcare Pharma Limited.
Class 2 Medicines Recall: Inhixa 12,000IU (120mg)/0.8mL solution for injection, Maxearn Limited, EL(25)A/27
Maxearn Limited have informed the MHRA that the carton used to package two imported batches of Inhixa have been released to the market with a typographical error on one side of the carton.
Guidance: Pharmacovigilance following agreement of the Windsor Framework
Information on the implementation of changes to pharmacovigilance for medicines authorised in the UK following the agreement of the Windsor Framework.
Sir David Spiegelhalter: Regulation in an age of personalised medicine
The internationally renowned expert in the calculation and communication of risk and statistics, Sir David Spiegelhalter, discusses the concept of a ‘preference zone’ to frame the demands of safety, efficacy and choice in the era of personalised medicine.
Class 4 Medicines Defect Notification: Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals NV, EL(25)A/37
Jubilant Pharmaceuticals NV has informed the MHRA that the Patient Information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.
Class 2 Medicines Recall: Accord Healthcare Ltd, Carmustine 100 mg Powder and Solvent for Concentrate for Solution for Infusion (1 vial 100mg powder, 1 vial of 3 mL solvent), EL(26)A/05
Accord Healthcare limited is recalling a single batch due to an out of specification test result.